
PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68, C12P 19/34, C07H 21/04, C07K 14/435, G01N 33/53		A1	Ì `	1) International Publication Number:	WO 98/24935
			(4	3) International Publication Date:	11 June 1998 (11.06.98)
 (21) International Application Number: PCT/US97/22105 (22) International Filing Date: 5 December 1997 (05.12.97) (30) Priority Data: 			BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,		
60/032.619	6 December 1996 (06.12.96	6) t	US	KE, LS, MW, SD, SZ, UG, ZW)	
60/032,701 60/041,576	12 December 1996 (12.12.9 24 March 1997 (24.03.97)	6) t	US US	BY, KG, KZ, MD, RU, TJ, TM) CH, DE, DK, ES, FI, FR, GB, PT, SE), OAPI patent (BF, BJ, ML, MR, NE, SN, TD, TG).	, European patent (AT, BE, GR, IE, IT, LU, MC, NL,
(71) Applicant (for all designated States except US): UROCOR, INC. [US/US]; 800 Research Parkway, Oklahoma City, OK				(viii, viii, 10, 10).	

(72) Inventors; and

73104 (US).

- (75) Inventors/Applicants (for US only): RALPH, David [US/US]; 2504 Stonehenge Drive, Edmond, OK 73034 (US). AN, Gang [CN/US]; 2609 N.W. 160th Street, Edmond, OK 73013 (US). O'HARA, Mark [US/US]; 130 N.W. 17th Street, Oklahoma City, OK 73101 (US). VELTRI, Robert [US/US]; 7301 N.E. 106th Street, Oklahoma City, OK 73151 (US).
- (74) Agent: CORDER, Timothy, S.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).

Published

With international search report.

(54) Title: DIAGNOSIS OF DISEASE STATE USING MRNA PROFILES

(57) Abstract

Disclosed are diagnostic techniques for the detection of a human diseased state. Genetic probes and methods useful in monitoring the progression and diagnosis of the disease state are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in the peripheral blood of individuals with the disease state compared to normal healthy individuals. Further disclosed is a multivariate diagnostic model for prostate cancer in a population of men with moderately elevated total serum PSA (≥ 2.0 ng/ml). Results of quantitative serum assays for the UC325 gene product [Interleukin–8 (IL–8)], total prostate specific antigen (t–PSA), as well as Free/Total (f/t PSA) ratios were combined to enhance the sensitivity of prostate cancer diagnosis in a defined urologic population diagnosed either organ–confined prostate cancer (clinical stage A & B), non–organ–confined prostate cancer (clinical stage C or D) or benign prostatic hyperplasia (BPH). The additional ability of UC325 gene product serum levels to accurately stage prostate cancer independently of t–PSA of f/t PSA is disclosed.

The remaining pages of this document are provided in electronic format on the attached compact disc.

Full paper copies will be provided upon request by the Examiner.